



# Nusinersen

## Adjudication Guideline

<b>Rule Category:</b> Pharmaceutical	<b>Ref: No:</b> 2022-PH-13	<b>Version Control:</b> Version No. V3.0	<b>Effective Date:</b> 15 <sup>th</sup> September 2022	<b>Revision Date:</b> 29/08/2025
<b>Approved by:</b> Daman	<b>Responsible:</b> Medical Standards & Research	<b>Related Adjudication Guidelines:</b>		

## Table of Contents

1.	Abstract .....	3
1.1	For Members.....	3
1.2	For Medical Professionals .....	3
2.	Scope .....	3
3.	Adjudication Policy.....	4
3.1	Eligibility / Coverage Criteria.....	4
3.2	Non-Coverage.....	5
3.3	Payment and Coding Rules .....	5
4.	Denial Codes.....	5
5.	Appendices .....	8
5.1	References .....	8
5.2	Revision History .....	8

## 1. Abstract

### 1.1 For Members

Nusinersen is an antisense oligonucleotide drug approved by the FDA for the treatment of spinal muscular atrophy.

Spinal muscular atrophy (SMA) is a genetic (inherited) neuromuscular disease that causes muscles to become weak and waste away.

Nusinersen is available in injection form and is administered intrathecal, or an injection into the fluid of the spine.

### 1.2 For Medical Professionals

Nusinersen is an antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

Spinal muscular atrophy (SMA) is a genetic (inherited) neuromuscular disease that causes muscles to become weak and waste away.

People with SMA are either missing part of the SMN1 gene on chromosome 5q or have a changed (mutated) gene. A healthy SMN1 gene produces SMN protein. People with SMA don't make enough SMN protein and lose a specific type of nerve cell in the spinal cord (called motor neurons) that control muscle movements.

Nusinersen is an intrathecal injection, or an injection into the fluid of the spine, by a healthcare professional experienced in performing lumbar punctures.

## 2. Scope

This Adjudication Rule highlights the medical indications and coverage requirements of Nusinersen for spinal muscular atrophy for all health insurance plans administered by Daman as per policy terms and conditions.

#### **Medical Indications:**

Nusinersen is an antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

#### **Different Types of SMA**

##### **Type 1 SMA (young babies)**

is the most common and severe form of SMA. It's sometimes called Werdnig-Hoffmann disease or infantile-onset SMA and it typically presents after birth but before age six months.

##### **Type 2 SMA (older babies and toddlers)**

is an intermediate form of SMA and shows symptoms when they're 6 to 18 months old.

##### **Type 3 SMA (children and young adults)**

is a milder form of SMA. It's also known as Kugelberg-Welander disease, and its Onset usually occurs between the age of 18 months and adulthood.

#### Type 4 SMA (adults)

is very rare. It usually starts in young adulthood and causes mild motor impairment.

#### Type 0 SMA (prenatal onset)

A very severe form of SMA, prenatal onset and is usually associated with early death from respiratory failure.

A pre-symptomatic SMA patient individual is defined as having the homozygous gene deletion or homozygous mutation, or compound heterozygous mutation of the SMN1 gene (Chromosome 5) found via pre-symptomatic testing of the patient. These patients are genetically destined to develop 5q SMA.

### 3. Adjudication Policy

#### 3.1 Eligibility / Coverage Criteria

##### Eligibility / Coverage Criteria

- Type I, II, III, and pre-symptomatic
- Confirmed genetic documentation of 5q SMA homozygous gene deletion or homozygous mutation, deletion, or compound heterozygous mutation.
- Age of the member is 15 years or younger at the start of the treatment.
- Must be prescribed by a neurologist.
- Must not be type 0 and type IV SMA patient.
- No permanent ventilation ( $\geq 16$  hours/day for 21 consecutive days in the absence of acute reversible infection) or permanent tracheostomy status.
- Member has not received gene replacement therapy previously for SMA (Ex: Zolgensma) or received gene replacement therapy earlier but worsened in clinical status.
- Nusinersen is not prescribed concurrently with Evrysdi or Zolgensma
- Should provide one of the following assessment tools as indicated by the patient motor ability:
  - 1) Hammersmith Infant Neurological Exam part-2 (HINE-2) or
  - 2) Hammersmith Functional Motor Scale Expanded (HFSME) or
  - 3) Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND).
  - 4) Revised Upper Limb Module (RULM)

##### Criteria for continuation of treatment

- I. All the above criteria are met.
- II. Initial evaluation should be done after 5 doses (4 loadings and 1 maintenance dose) and the member should show a positive clinical response from pre-treatment baseline to Nusinersen treatment as demonstrated by at least one of the following assessments:
  - A. **HINE:** Member shows improvement of at least:
    - i. 2 points horizontal kick or
    - ii. 1 point on other HINE scores (Ex: rolling, crawling, sitting, standing, head control, or walking) excluding voluntary grasp.
  - B. **HFSME:** improvement of at least 3 points.
  - C. **CHOP INTEND:** Member should exhibit at least 4 points of improvement on this scale.
  - D. **RULM:** At least a 2-point increase in score from pre-treatment baseline.
- III. 12month periodic re-examination must be done.

## 3.2 Non-Coverage

Off-label uses of Nusinersen that are not an FDA-approved indication or not included in the Coverage Criteria 'section of this policy is considered experimental/investigational or not a covered benefit of this policy.

Plan	Coverage
Visitor plan	Not covered
Basic plan	Not covered
Enhanced plan	Covered as per SOB
Thiqa	Covered

Eligible clinician specialty
Neurosurgery
Neurology
Pediatric Neurology
Neurological Surgery
Clinical Neurophysiology
Pediatric Neurology/ Clinical Neurophysiology

## 3.3 Payment and Coding Rules

Kindly apply DOH payment rules and regulations and relevant coding manuals for ICD, Drugs.

## 4. Denial Codes

Code	Code Description
MNEC-003	Service is not clinically indicated based on good clinical practice
MNEC-005	Service/ supply may be appropriate, but too frequent.
CODE-010	Activity/diagnosis inconsistent with clinician specialty
NCOV-003	Service(s) is (are) not covered
Auth-001	Prior approval is required and was not obtained

Kindly use the below Pre-Approval Form for Authorization:

[https://www.damanhealth.ae/main/pdf/support/Questionnaire/NUSIRENSEN\\_QUESTIONNAIRE.pdf](https://www.damanhealth.ae/main/pdf/support/Questionnaire/NUSIRENSEN_QUESTIONNAIRE.pdf)

## Spinraza Pre-Authorization Form



### MEMBER INFORMATION

- Member Name: \_\_\_\_\_
- Member Card #: \_\_\_\_\_
- Policy: \_\_\_\_\_
- Date:    /    / 202\_\_\_\_\_
- Age: \_\_\_\_\_
- Gender:  Female     Male

### PROVIDER INFORMATION

- Ordering Provider Name: \_\_\_\_\_
- Ordering Clinician (ID # & Name): \_\_\_\_\_
- Performing Provider Name: \_\_\_\_\_
- Performing Clinician Specialty (ID # & Name): \_\_\_\_\_
- Referring Physician Contact No.: \_\_\_\_\_

### SERVICE REQUESTED

Principal/ Primary Diagnosis: \_\_\_\_\_ ICD-10: \_\_\_\_\_

Medication (Spinraza) Dosage: \_\_\_\_\_ Quantity: \_\_\_\_\_

Treatment initiation date: \_\_\_\_\_

Requested Dosage     Initial dose     Maintenance dose

Age of the member at the initiation of the treatment: \_\_\_\_\_

### Motor ability assessment

1) Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorder (CHOP-INTEND) score: Not applicable

Baseline score: \_\_\_\_\_ Date tested: \_\_\_\_\_ ; Current score: \_\_\_\_\_ Date tested: \_\_\_\_\_

2) Hammersmith Infant Neurological Exam part-2 (HINE-2) score: Not applicable

Baseline score: \_\_\_\_\_ Date tested: \_\_\_\_\_ ; Current score: \_\_\_\_\_ Date tested: \_\_\_\_\_

3) Revised Upper Limb Module (RULM) score: Not applicable

Baseline score: \_\_\_\_\_ Date tested: \_\_\_\_\_ ; Current score: \_\_\_\_\_ Date tested: \_\_\_\_\_

4) Hammersmith Functional Motor Scale Expanded (HFMSE) motor milestone score: Not applicable

Baseline score: \_\_\_\_\_ Date tested: \_\_\_\_\_ ; Current score: \_\_\_\_\_ Date tested: \_\_\_\_\_

### MEMBER CONFIDENTIAL

National Health Insurance Company - Daman (PJSC) (P.O. Box 128888, Abu Dhabi, U.A.E. Tel No. +97126149555 Fax No. +97126149550)

Doc Ctrl No.:	F/6031	Version No.:	1	Revision No.:	0	Date of Issue:	07.03.2019	Page No(s.):	1 of 2
---------------	--------	--------------	---	---------------	---	----------------	------------	--------------	--------

Spinraza Pre-Authorization Form



**Additional information**

- 1) Genetic test confirmation of the Spinal muscular atrophy (SMA)  Yes  No
- 2) Patient requires tracheostomy or invasive or non-invasive ventilation ≥16 hours/day for 21 consecutive days  
 Yes  No
- 3) Spinraza prescribed concurrently with Evrysdi or Zolgensma Yes  No
- 4) Previously treated with Zolgensma  No  
 Yes (Documented evidence of worsening clinical status)

**MEMBER CONFIDENTIAL**

National Health Insurance Company – Daman (PJSC) (P.O. Box 128888, Abu Dhabi, U.A.E. Tel No. +97126149555 Fax No. +97126149550)

Doc Ctrl No.:	F/6031	Version No.:	1	Revision No.:	0	Date of Issue:	07.03.2019	Page No(s.):	2 of 2
---------------	--------	--------------	---	---------------	---	----------------	------------	--------------	--------

## 5. Appendices

### 5.1 References

- A. [https://www.spinraza.com/content/dam/commercial/spinraza/caregiver/en\\_us/pdf/spinraza-prescribing-information.pdf](https://www.spinraza.com/content/dam/commercial/spinraza/caregiver/en_us/pdf/spinraza-prescribing-information.pdf)
- B. <https://www.ema.europa.eu/en/medicines/human/EPAR/spinraza>
- C. <https://www.nhs.uk/conditions/spinal-muscular-atrophy-sma/types/>
- D. <https://www.uptodate.com/contents/spinal-muscular-atrophy>
- E. <https://www.nhs.uk/conditions/spinal-muscular-atrophy-sma/diagnosis/>
- F. *Spinraza 12 mg solution for injection - Summary of Product Characteristics (SmPC) - (emc) (medicines.org.uk)*
- G. <https://www.nice.org.uk/guidance/ta588/resources/managed-access-agreement-july-2019-pdf-6842812573>
- H. [https://www.spinraza-hcp.com/content/dam/commercial/spinraza/hcp/en\\_us/pdf/mobility-and-physical-ability](https://www.spinraza-hcp.com/content/dam/commercial/spinraza/hcp/en_us/pdf/mobility-and-physical-ability)
- I. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2023/209531s011lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209531s011lbl.pdf)
- J. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2024/209531s013s014lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209531s013s014lbl.pdf)

### 5.2 Revision History

Date	Change(s)
15/8/2022	Release of V1.0
23/5/2023	Updated: questionnaire link
16/08/2024	AR review
30/10/2024	No changes/ updated in the new AR format
29/08/2025	AR Review

#### Disclaimer

By accessing these Daman Adjudication Guidelines, you acknowledge that you have read and understood the terms of use set out in the disclaimer below:

The information contained in this Adjudication Guideline is intended to outline the procedures of adjudication of medical claims as applied by the National Insurance Company – Daman PJSC (hereinafter “Daman”). The Adjudication Guideline is not intended to be comprehensive, should not be used as treatment guidelines and should only be used for the purpose of reference or guidance for adjudication procedures and shall not be construed as conclusive. Daman in no way interferes with the treatment of patient and will not bear any responsibility for treatment decisions interpreted through Daman Adjudication Guideline. Treatment of patient is and remains at all times the sole responsibility of the treating Healthcare Provider. This Adjudication Guideline does not grant any rights or impose obligations on Daman. The Adjudication Guideline and all of the information it contains are provided “as is” without warranties of any kind, whether express or implied which are hereby expressly disclaimed.

Under no circumstances will Daman be liable to any person or business entity for any direct, indirect, special, incidental, consequential, or other damages arising out of any use of, access to, or inability to use or access to, or reliance on this Adjudication Guideline including but without limitation to, any loss of profits, business interruption, or loss of programs or information, even if Daman has been specifically advised of the possibility of such damages. Daman also disclaims all liability for any material contained in other websites linked to Daman website.

This Adjudication Guideline is subject to the laws, decrees, circulars and regulations of Abu Dhabi and UAE. Any information provided herein is general and is not intended to replace or supersede any laws or regulations related to the Adjudication Guideline as enforced in the UAE issued by any governmental entity or regulatory authority, or any other written document governing the relationship between Daman and its contracting parties.

This Adjudication Guideline is developed by Daman and is the property of Daman and may not be copied, reproduced, distributed or displayed by any third party without Daman’s express written consent. This Adjudication Guideline incorporates the Current Procedural Terminology (CPT®), which is a registered trademark of the American Medical Association (“AMA”) and the CPT codes and descriptions belong to the AMA. Daman reserves the right to modify, alter, amend or obsolete the Adjudication Guideline at any time by providing one month prior notice.